Cathie Wood
FPRX

Cathie Wood’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Cathie Wood’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-183,094
Closed -$2.9M – 209
2018
Q2 		$2.9M Buy
183,094
+114,240
+166% +$1.99M 0.11% 77
2018
Q1 		$1.18M Buy
68,854
+25,639
+59% +$500K 0.06% 98
2017
Q4 		$947K Buy
43,215
+21,211
+96% +$682K 0.08% 101
2017
Q3 		$900K Buy
22,004
+7,830
+55% +$246K 0.11% 92
2017
Q2 		$427K Buy
14,174
+10,623
+299% +$332K 0.08% 85
2017
Q1 		$128K Buy
3,551
+351
+11% +$15.5K 0.04% 90
2016
Q4 		$160K Buy
+3,200
New +$168K 0.06% 84

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Cathie Wood's FPRX Position: Q3 2018 in Review

Cathie Wood sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2018, closing a stake of 183,094 shares — an estimated $2.9M sold.

Cathie Wood first reported a position in FPRX in Q4 2016 and held it in 7 quarters. The position peaked at $2.9M in Q2 2018. 114 funds tracked by Wall St. Rank hold FPRX as of Q3 2018.

  • Cathie Wood reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Cathie Wood sold 183,094 Five Prime Therapeutics, Inc. shares in Q3 2018, an estimated $2.9M.
  • Cathie Wood first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 7 quarters.
  • Cathie Wood's Five Prime Therapeutics, Inc. position peaked at $2.9M in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2018.

Based on ARK Investment Management's 13F filing for Q3 2018, filed 7 Nov 2018.